You searched for "neovascular"

1165 results found

Stent inject® W shelf life extended from 12 months to three years

Glaukos is delighted to announce that the expiry date for their innovative iStent inject® W device has been increased from 12 months to three years.

50th Trends in Ophthalmology meeting: 13th & 14th March 2025

The 50th anniversary of St Thomas’ ‘Trends in Ophthalmology’ meeting, will be two days of exciting discussions, presentations, and networking opportunities with leading experts in the field. This meeting will be extra special as we are also celebrating 75 years...

Canadian centre experience with ocular cystinosis cases

Ocular cystinosis (OC) is an uncommon recessive genetic disease occurring in about one case per 100–200,000 live births. Patients have accumulation of cystine crystals within tissues. Ocular symptoms include photophobia, blepharospasm, foreign body sensation, retinopathy and visual impairment. Crystals have...

What's trending Dec/Jan 2019

The Eye News Twelve Days of Christmas On the first day of Christmas, my true love gave to me…A #RyderCup globe injury An unfortunate spectator was hit in the eye by a wayward golf ball during the Ryder Cup, and...

DR-NET National DR Workshop in Tanzania: Policy, training and technology

Diabetic retinopathy (DR) is a leading cause of moderate to severe visual impairment (VI) and blindness worldwide, posing a significant public health challenge. As the prevalence of diabetes continues to rise globally, particularly in low- and middle-income countries (LMICs), the...

Sustainability in eyecare: Are virtual clinics the way forward in the diagnosis and monitoring of retinal disease?

Virtual clinics can be used successfully in screening and management of ocular conditions such as diabetic retinopathy, retinopathy of prematurity and age-related macular degeneration. Virtual clinics should be a considered as a more clinically appropriate modality of consultation, diagnosis and...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...

Innovative 3D printing could revolutionise treatment for cataracts and other eye conditions

University of East Anglia researchers have made a significant breakthrough in ocular device technology with the introduction of a novel resin for 3D printing intraocular devices. This innovation has potential to enhance the manufacture of eye implants universally used in cataract and refractive surgeries.

Managing cataract surgery in a patient with diabetic maculopathy

A 56-year-old type 2 diabetic with previously treated bilateral diabetic maculopathy develops a cataract requiring surgery in the right eye. He has had grid laser previously, followed intermittently by intravitreal triamcinalone, Avastin and more recently Lucentis in both eyes. His...

The results of the last survey Feb21

Once again, I am grateful for the responses and read the results with interest. I am always surprised by the amount of practice variation I see. I fully accept there is art in what we do and there is no...

A single intravitreal bevacizumab in the treatment of breast carcinoma related choroidal metastasis

Case report Choroidal metastasis represents a common form of intraocular malignancies occurring in up to 10% of patients with systemic metastasis [1]. The most common primary sites of ocular metastasis are breast carcinoma in women and lung carcinoma in men,...

Acute uveitis from late migration of soft lens matter 10 years post cataract surgery

A 58-year-old Caucasian male presented to the emergency eye clinic with a two-day history of a painful, red left eye and blurred vision. His past ocular history included uncomplicated left phacoemulsification cataract surgery in 2010 and left retinal detachment repair...